Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • KPT-276: A Source-Bounded CRM1 Export Overview

    2026-10-16

    KPT-276 is described by APExBIO as a selective inhibitor of nuclear export (SINE) directed against chromosomal maintenance protein 1, also called exportin 1 (CRM1/XPO1). The available evidence is limited to the supplier’s product description rather than an identity-matched research article. Accordingly, the mechanism and biological findings below should be read as documented product claims, not as an independently verified literature synthesis. The relevant product record is KPT-276, listed by APExBIO under SKU B1463.

    1. Documented identity and scientific context

    The product description identifies KPT-276 as a solid compound with the stated molecular formula C16H10F8N4O and molecular weight 426.26. It gives the chemical name “(Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one.” These details establish the identity represented by the commercial record; they do not, by themselves, establish purity, batch equivalence, target engagement, or biological performance in a particular study.

    CRM1/XPO1 is presented in the description as a nuclear export receptor responsible for transporting classes of proteins and RNA from the nucleus to the cytoplasm. The biological context is therefore not a single oncogenic pathway but a transport process that can affect transcription factors, cell-cycle regulators, tumor suppressors, and RNA species. The supplier further states that CRM1 overexpression or hyperactivity is implicated in several cancers. That statement provides the rationale for studying export inhibition in cancer models, but it does not demonstrate that every tumor depends on CRM1 to the same extent or that a response attributed to KPT-276 is uniform across disease contexts.

    2. Documented mechanism and measurement principle

    From export-receptor binding to cellular readouts

    According to the product description, KPT-276 irreversibly binds CRM1 and blocks CRM1-mediated nuclear export. In conceptual terms, this is the proposed upstream event: interference with an export receptor should alter the intracellular distribution of its cargoes. The described downstream interpretation is that tumor suppressors and other regulatory proteins become preferentially retained in the nucleus, changing transcriptional and cell-cycle control.

    The same description associates this blockade with reduced levels or activity of oncogenic proteins including c-MYC, CDC25A, and BRD4, followed by G1/S-phase cell-cycle arrest and apoptosis. These observations occupy different levels of biological interpretation:

    • CRM1 binding and export blockade are the proposed initiating molecular mechanism.
    • Nuclear retention of regulatory cargoes is the proposed proximal consequence of that blockade.
    • Changes involving c-MYC, CDC25A, and BRD4 are downstream molecular correlates reported in the product narrative.
    • G1/S arrest and apoptosis are cellular phenotypes that may be compatible with the proposed mechanism but do not, on their own, prove that CRM1 inhibition caused them.

    This distinction matters because a viability decrease or apoptotic signal is a downstream outcome, whereas target engagement and altered nuclear-cytoplasmic distribution would address the upstream mechanism more directly. The supplied information does not provide assay designs, quantitative target-engagement measurements, localization data, matched controls, or independent mechanistic perturbations. It therefore supports a mechanistic hypothesis and a supplier-reported interpretation, rather than a complete causal chain established by the available record.

    What the reported measurements mean

    The product description states that KPT-276 reduced viability of human myeloma cell lines with an IC50 of approximately 160 nM. An IC50 is a concentration associated with a 50% reduction in the measured response under the unspecified assay context; it is not a universal potency constant and cannot be compared rigorously across cell lines or laboratories without the assay definition, exposure history, replicate structure, and curve uncertainty.

    The description also states that KPT-276 induced apoptosis in bone-marrow cells from patients with multiple myeloma (MM). This links the reported phenotype to patient-derived material, but the excerpt does not identify the number of specimens, clinical characteristics, comparator populations, or apoptosis measurement. The observation is therefore relevant to translational context while remaining insufficient to establish patient selectivity, therapeutic index, or clinical efficacy.

    3. Interpretation of the supplied properties and scope

    Cellular and disease-model scope

    The stated biological scope includes MM and acute myeloid leukemia (AML) models. The supplier reports both apoptosis induction in cancer cells and inhibition of tumor growth in xenograft mice. These are related but non-equivalent claims: cell viability and apoptosis assays address cellular response in defined model systems, whereas xenograft growth integrates tumor-cell biology with host exposure, tissue distribution, and the behavior of the implanted tumor in an animal.

    For the in vivo setting, the product description reports that oral administration in xenograft mouse models significantly inhibited tumor growth, reduced spleen weight, decreased white blood cell counts, and improved survival. It does not provide group sizes, absolute or relative effect sizes, confidence intervals, statistical tests, tumor-model identities, or the duration of follow-up. “Significant” therefore cannot be independently assessed from the supplied information. Reduced spleen weight and white blood cell counts are also not specific measures of antitumor action: they may reflect changes in disease burden, hematopoiesis, systemic exposure, or other host effects. Their interpretation requires model-specific controls and toxicity data that are not included here.

    The oral-administration statement supports the existence of a reported in vivo route in the supplier narrative, but it should not be treated as a complete demonstration of oral bioavailability, pharmacokinetics, exposure-response relationships, or suitability for human treatment. Likewise, the product’s stated insolubility in water and ethanol and solubility in DMSO are physicochemical descriptors, not evidence of a biological mechanism or of performance in a particular assay.

    Claim, reported evidence, and interpretation

    Claim in the product description Reported evidence Proportionate interpretation
    Selective inhibition of nuclear export KPT-276 is described as targeting CRM1/XPO1 and irreversibly binding the receptor. This defines the proposed molecular target and mechanism, but the supplied record does not include an identity-matched binding or target-engagement study.
    Cell-cycle and apoptotic effects The description links export blockade with c-MYC, CDC25A, and BRD4 changes, G1/S arrest, and apoptosis. These are mechanistically coherent downstream claims, but the excerpt does not establish which measurements were direct, how they were controlled, or whether each effect was causally dependent on CRM1.
    Activity in MM models Reduced viability was reported in human myeloma cell lines, with an IC50 around 160 nM; apoptosis was reported in bone-marrow cells from MM patients. The approximate IC50 supplies a quantitative anchor, while missing assay and sample details limit cross-study comparison and translational inference.
    Tumor growth inhibition in vivo The supplier reports reduced xenograft growth, spleen weight, and white blood cell counts, together with improved survival. The direction of the reported findings is clear, but the magnitude, precision, model-specific relevance, and contribution of systemic toxicity cannot be evaluated from the excerpt.

    4. Evidence availability and specific boundaries

    No matched paper is available for the named KPT-276 record. There are also no related articles in the supplied material that permit a direct comparison with another KPT-276 study, another CRM1 inhibitor, or a matched control compound. Consequently, the product page is the provenance for the identity, mechanism narrative, approximate cellular IC50, and reported MM, AML, and xenograft outcomes discussed here.

    Several boundaries follow from that provenance:

    • The stated CRM1 mechanism is documented as a supplier description, not independently corroborated here by biochemical, localization, genetic, or pharmacological evidence.
    • The approximate 160 nM IC50 is not accompanied by cell-line names, assay endpoint, replicate number, uncertainty, or comparator information. It should not be generalized to all myeloma cells or treated as a clinical exposure threshold.
    • The patient-derived bone-marrow result lacks specimen numbers and clinical metadata, so it cannot establish reproducibility, patient subgroup response, or preferential tumor-cell toxicity.
    • The xenograft claims lack model identifiers, cohort sizes, effect estimates, variability measures, and detailed safety observations. Tumor growth inhibition and survival improvement therefore remain reported directional findings rather than fully assessable efficacy estimates.
    • Changes in spleen weight and white blood cell counts are biologically informative but nonspecific. Without model-specific context, they cannot be assigned solely to tumor reduction or interpreted as evidence of an acceptable therapeutic window.
    • Information about the commercial material does not establish that any particular research study used APExBIO’s product. The supplier relationship documents product availability, not study provenance.

    These limitations also constrain cross-domain extrapolation. Findings in cell lines cannot by themselves predict responses in primary tumors, and xenograft outcomes cannot establish human efficacy. Similarly, the presence of an export-related mechanism does not imply that all CRM1 cargoes, cancer types, or treatment contexts will respond in the same way.

    5. Concise factual synthesis

    KPT-276 is presented by APExBIO as a SINE compound targeting CRM1/XPO1, with a proposed mechanism of irreversible receptor binding and CRM1-mediated nuclear export blockade. The associated biological narrative is nuclear retention of regulatory proteins, changes involving c-MYC, CDC25A, and BRD4, G1/S-phase arrest, and apoptosis. The supplier reports an approximate 160 nM IC50 for reduced viability in human myeloma cell lines, apoptosis in bone-marrow cells from patients with MM, and tumor growth inhibition with survival improvement in xenograft mouse models.

    The strongest defensible conclusion from the available material is that KPT-276 is a commercially identified CRM1/XPO1 export-inhibition research compound with a supplier-documented rationale and reported activity across cellular and animal cancer models. The evidence does not, on its own, establish independent target validation, comparative potency, quantitative in vivo efficacy, safety, or clinical utility. Those questions remain outside what can be concluded from the product description alone.